Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants had to meet the following criteria to be included:~* Willing and able to read, understand, and sign an informed consent form~* Confirmed diagnosis of WAIHA by enrolling physician~* Must have used medically acceptable contraception~Exclusion Criteria:~Participants who met any of the following criteria were excluded:~* Participant unable or unwilling to comply with the protocol~* Active non-hematologic malignancy or history of non-hematologic malignancy in the 3 years prior to screening (exclusive of non-melanoma skin cancer and cervical cancer in situ)~* Positive for human immunodeficiency virus or hepatitis C antibody~* Positive for hepatitis B surface antigen~* Any exposure to an investigational drug or device within the 30 days prior to screening~* Intravenous immunoglobulin treatment within 30 days of screening~* Plasmapheresis or immunoadsorption within 30 days of screening~* Participant had any current medical condition that, in the opinion of the Investigator, may have compromised their safety or compliance, precluded successful conduct of the study, or interfered with interpretation of the results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: ALXN1830 (Type: EXPERIMENTAL): SYNT001 Dose 1
- Cohort 2: ALXN1830 (Type: EXPERIMENTAL): SYNT001 Dose 2

Based on this trial design, predict the completion outcome and termination type (if applicable).